Monday, September 21, 2026
Science

Engineered nanoparticles sensitize gliomas to radiotherapy

Gliomas are a major cause of cancer-related deaths in younger adults. About 7,000 patients harbor a common genetic mutation that affects the enzyme isocitrate dehydrogenase 1. This mutated enzyme, called mIDH1, can produce a molecule that can reprogram both the tumor cells and the environment in whi...

Engineered nanoparticles sensitize gliomas to radiotherapy
Image: Phys.org
Gliomas are a major cause of cancer-related deaths in younger adults. About 7,000 patients harbor a common genetic mutation that affects the enzyme isocitrate dehydrogenase 1. This mutated enzyme, called mIDH1, can produce a molecule that can reprogram both the tumor cells and the environment in which they grow. The molecule, known as 2-hydroxyglutarate, can also circulate in the blood and reprogram immune cells in the bone marrow.

Originally published at Phys.org

The Morning Briefing

Subscribe to our Newsletter

Be the first to receive the latest news, market analysis and updates — delivered straight to your inbox.